The U.S. Food and Drug Administration (FDA) has approved ketorolac tromethamine nasal spray (Sprix) for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

SPRIX is a prescription only intranasal formulation of the ketorolac designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute moderate to moderately severe pain relief.

[Editors note: Intranasal ketorolac is currently not available in the UK.]